Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
3.02% $0.603
America/New_York / 26 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 20.88 mill |
EPS: | -3.09 |
P/E: | -0.200 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 34.62 mill |
Avg Daily Volume: | 0.293 mill |
RATING 2024-04-26 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.200 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.200 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.541 - 0.665 ( +/- 10.28%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-10 | Sun Kevin M | Sell | 445 | Common Stock |
2024-03-05 | Sun Kevin M | Buy | 0 | |
2024-03-05 | Akhavan Ramin | Sell | 1 758 | Common Stock |
2024-03-05 | Akhavan Ramin | Sell | 1 989 | Common Stock |
2024-03-05 | Sun Kevin M | Sell | 180 | Common Stock |
INSIDER POWER |
---|
72.33 |
Last 97 transactions |
Buy: 1 415 350 | Sell: 282 150 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.603 (3.02% ) |
Volume | 0.0863 mill |
Avg. Vol. | 0.293 mill |
% of Avg. Vol | 29.50 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.